Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

New England Journal of Medicine
May 20, 2021 Vol. 384 No. 20
http://www.nejm.org/toc/nejm/medical-journal

 

Original Articles
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
Shabir A. Madhi, Ph.D., et al for the NGS-SA Group, and the Wits-VIDA COVID Group*
Conclusions
A two-dose regimen of the ChAdOx1 nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT04444674. opens in new tab; Pan African Clinical Trials Registry number, PACTR202006922165132. opens in new tab).